An international study examined outcomes between a single-port (SP) versus a multi-port (MP) approach to RAPN, with a focus on elderly patients. Despite similar demographics among patients ≤64 years ...

A large national study in Denmark following nearly 1,900 patients over almost a decade has found that a minimally invasive ...

At 24 months overall survival was 62.8% with Welireg plus Lenvima versus 55.4% with Cabometyx. Median overall survival was 34 ...

The combination of belzutifan plus lenvatinib significantly improved outcomes for patients with clear cell renal cell carcinoma who progressed following immunotherapy compared with cabozantinib ...

The US Food and Drug Administration (FDA) has approved belzutifan (Welireg) for adults with advanced renal cell carcinoma following progression on a PD-1/L1 inhibitor and a vascular endothelial growth ...

Patients with a common form of kidney cancer called clear cell renal cell carcinoma (ccRCC) who have a high risk of recurrence after surgery showed significantly improved disease-free survival when ...

Moderate to advanced chronic kidney disease is an underappreciated burden of von Hippel-Lindau (VHL)-associated renal cell carcinoma (RCC) treated with surgery, which also includes frequent disease ...

—When upper tract urothelial carcinoma strikes a patient with a single kidney, the decision between kidney-sparing surgery and radical nephroureterectomy can be complicated. These investigators ...

The incidence of renal cell carcinoma among the included patients with Fabry disease was 15 times higher than in the general population. Patients with Fabry disease appear to have a higher incidence ...

In a double-blind, randomized trial involving nearly 1000 patients followed for a median of 2 years, pembrolizumab injections for 1 year after surgery led to improved disease-free survival at 24 ...